Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Long-Term Deferred Tax (2022 - 2023)

InMed Pharmaceuticals' Long-Term Deferred Tax history spans 2 years, with the latest figure at $21.0 million for Q2 2023.

  • For Q2 2023, Long-Term Deferred Tax rose 12.56% year-over-year to $21.0 million; the TTM value through Jun 2023 reached $21.0 million, up 12.56%, while the annual FY2023 figure was $21.0 million, 12.56% up from the prior year.
  • Long-Term Deferred Tax reached $21.0 million in Q2 2023 per INM's latest filing, up from $18.7 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $21.0 million in Q2 2023 to a low of $18.7 million in Q2 2022.